Clinical Trial Update: A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

Ipsen is conducting a Phase 1/2 trial of IPN01194 as a single-agent therapy for adults with advanced solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Pancreatic Ductal Adenocarcinoma
• Solid Tumors

Drugs mentioned

• IPN01194

Snippet

Sponsor: Ipsen | Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING